Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
InhaleRx Limited ( (AU:IRX) ) has issued an update.
InhaleRx Limited has announced the appointment of Tony Fitzgerald as a director, replacing James Barrie who has resigned but will remain as Company Secretary. Fitzgerald brings extensive experience in the life sciences and technology sectors, potentially enhancing the company’s strategic direction and industry positioning.
More about InhaleRx Limited
InhaleRx Limited is an Australian healthcare company focused on developing unique inhaled drug-device products aimed at addressing unmet medical needs in the pain management and mental health sectors. The company’s goal is to secure U.S. FDA approval through cost-effective regulatory pathways and is currently investigating treatments for Breakthrough Cancer Pain and Panic Disorder, supported by its innovation and provisional patents.
YTD Price Performance: -45.00%
Average Trading Volume: 127,268
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: A$4.7M
For detailed information about IRX stock, go to TipRanks’ Stock Analysis page.
